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Abstract.  SPARC (Secreted Protein Acidic and Rich 
in Cysteine) is a Ca÷2-binding  glycoprotein that is 
differentially associated with morphogenesis,  remodel- 
ing,  cellular migration,  and proliferation.  We show 
here that exogenous SPARC, added to cells in culture, 
was associated with profound changes in cell shape, 
caused rapid,  partial detachment of a confluent 
monolayer, and inhibited spreading of newly plated 
cells. 
Bovine aortic endothelial cells, exposed to 2-40/zg 
SPARC/ml per 2  x  106 cells, exhibited a rounded 
morphology in a dose-dependent manner but remained 
attached to plastic or collagen-coated surfaces.  These 
round cells synthesized protein,  uniformly excluded 
trypan blue, and grew in aggregates after replating  in 
media without SPARC.  SPARC caused rounding of bo- 
vine endothelial cells, fibroblasts, and smooth muscle 
cells; however, the cell lines F9, PYS-2, and 3T3 were 
not affected. The activity of native SPARC was in- 
hibited by heat denaturation  and prior incubation with 
anti-SPARC IgG.  The effect of SPARC on endothelial 
cells appeared to be independent of the rounding 
phenomenon produced by the peptide GRGDSP. Im- 
munofluorescence localization of SPARC on en- 
dothelial cells showed preferential distribution at the 
leading edges of membranous extensions. 
SPARC bound Ca  ÷2 in both amino- and carboxyl- 
terminal  (EF-hand) domains and required this cation 
for maintenance of native structure.  Solid-phase bind- 
ing assays indicated a preferential affinity of native 
SPARC for several proteins comprising the extracellu- 
lar matrix,  including types III and V  collagen, and 
thrombospondin.  This binding was saturable,  Ca  +2 de- 
pendent,  and inhibited by anti-SPARC IgG.  En- 
dothelial cells also failed to spread on a  substrate of 
native type III collagen complexed with SPARC.  We 
propose that SPARC is an extracellular modulator of 
Ca  ÷2 and cation-sensitive proteins or proteinases, 
which facilitates changes in cellular shape and disen- 
gagement of cells from the extracellular matrix. 
C 
ELLULAR responses to certain  types of injury  and 
developmental  signals often involve expression of the 
same genes.  Vascular endothelial  cells interact  with 
components of the extracellular  matrix during angiogenesis, 
intercellular  adhesion, signal transduction,  and maintenance 
of thromboresistance (Herman,  1987; Nicosia and Madri, 
1987; Rodgers,  1988).  A consequence of such interactions 
is the induction  of gene products that facilitate or modulate 
cellular  behavior.  Studies  from  several  laboratories  have 
identified  one of these gene products as SPARC (Secreted 
Protein  Acidic  and  Rich  in  Cysteine),  a  secreted  Ca  ÷2- 
binding  protein that  is associated with 'cellular  differentia- 
tion, proliferation,  stress, and certain developmental  signals 
(Mason et al.,  1986a,b; Sage et al.,  1986; Holland et al., 
1987).  Molecular  cloning  and  protein  sequence analysis 
have shown that SPARC is identical to osteonectin, a protein 
originally  described in bone but also found in platelets  and 
fibroblasts  (Termine et al.,  1981; Otsuka et al.,  1984; Wasi 
et al.,  1984;  Mason et al.,  1986b;  Stenner  et al.,  1986; 
Young et al., 1986; Zung et al., 1986; Bolander et al., 1988). 
SPARC is also identical to BM-40, a product of a basement 
membrane-secreting tumor cell line (Dziadek et al.,  1986; 
Mann et al., 1987), and to a 43-kD glycoprotein, synthesized 
in vitro by cells of the vessel wall, as well as other normal 
and  transformed  cells (Sage  et al.,  1981a, 1984).  In  en- 
dothelial cells this protein was identified as a "culture shock" 
protein that bound BSA and a 70-kD serum protein and was 
increased after endotoxin-mediated  injury (Sage,  1986a,b; 
Sage et al.,  1986). 
The SPARC single-copy gene has been localized to mouse 
chromosome 11 in a region identified with several develop- 
mental  anomalies (Mason et al.,  1986a).  SPARC is highly 
conserved with 92 % sequence identity  between the bovine 
and  mouse protein  (Bolander et al.,  1988;  Engel  et al., 
1987).  The amino acid sequence revealed  four unique do- 
mains:  I, an acidic, Ca÷2-binding region;  II, a Cys-enriched 
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ical sequence containing a serine protease-sensitive site; and 
IV, a Ca+2-binding EF-hand as found in other high affinity 
Ca+2-binding proteins (Mason et al.,  1986b;  Engel et al., 
1987). The affinity of SPARC for Ca  +2 (3  ×  10  -7 M) (Rom- 
berg et al.,  1985) is similar to that of calmodulin. 
Since bone osteonectin/SPARC is now known to be a po- 
tent inhibitor of hydroxyapatite formation (Romberg et al., 
1985),  it has been suggested that the protein might inhib- 
it  (Engel  et  al.,  1987)  rather  than  promote  (Termine  et 
al.,  1981) extracellular mineralization. Recent studies have 
shown tissue-specific and developmentally related expres- 
sion of SPARC mRNA in fetal and adult mice (Holland et 
al., 1987). This work, as well as immunohistochemical data 
(Tung et al., 1985; Sage et al., 1989a,b), provided evidence 
for the association of SPARC with proliferating cells in sev- 
eral tissues. While the presence of SPARC in basement mem- 
branes and extracellular interstitia in vivo is controversial 
(Termine et al., 1981; Wasi et al.,  1984; Tung et al.,  1985; 
Dziadek et al., 1986; Sage et al., 1989a,b), it was found not 
to be incorporated into newly synthesized extracellular ma- 
trix by several different cell types which secrete the protein 
in vitro (Mason et al.,  1986b;  Sage et al.,  1986). 
In this study we have addressed the function of SPARC as 
a secreted but nonmatrix protein showing up-regulation dur- 
ing cellular migration and/or proliferation in vitro. We show 
that addition of purified SPARC to cells in culture elicited a 
rounded morphology that was correlated with an inhibition 
of cellular spreading.  This effect of SPARC  was  specific, 
dose-dependent, Ca  ÷2 sensitive, and nontoxic. The change 
in shape was accompanied by limited cellular aggregation 
and  appeared  distinct  from  an  RGD-related  mechanism 
(Hynes, 1987).  Exogenous SPARC was localized to leading 
edges of  extensions of  the endothelial cell plasma membrane. 
We also demonstrate that SPARC bound specifically to sev- 
eral components of extracellular matrix: type III collagen, 
type V collagen, and thrombospondin. Since these proteins, 
as well as SPARC, are produced by endothelial cells, smooth 
muscle cells (SMCs),~ and fibroblasts of the vessel wall (Sage 
et al.,  1981a, 1984;  Mumby et al.,  1984b;  Wight et al., 
1985; Sage,  1986b),  we propose that the rounding effect of 
SPARC on endothelial cells is mediated through an interac- 
tion of SPARC with specific matrix proteins. This interaction 
would be permissive for cellular migration and proliferation. 
Materials and Methods 
Cell Culture 
Bovine aortic endothelial (BAE) cells and bovine aortic SMCs at low pas- 
sage numbers were obtained from Dr. S. Schwartz (University of Washing- 
ton, Seattle, WA) and were cultured as previously described (Sage et al., 
1986).  Bovine fetal calf ligament (FCL) fibroblasts and additional strains 
of BAE cells were prepared in our laboratory and grown in DME containing 
10% FCS and antibiotics (Sage and Mecham, 1987).  Swiss 3T3 cells (clone 
DI) were grown as described by Pentinnen et al. (1988).  F9 cells were pur- 
chased from the American Type Culture Collection (Rockville, MD) and 
grown on gelatin-coated tissue culture plasticware in DME supplemented 
with 10% FCS. Mouse parietal ~lk sac (PYS)-2 cells, gifts from Drs. B. 
Hogan (Vanderbiit University, Nashville, TN) and J. Lehman (Albany Med- 
ical College, Albany, NY), were cultured in DME containing 10% FCS and 
were passaged approximately twice per week. Experiments were performed 
1. Abbreviations used in this paper: BAE, bovine aortic endothelial; FCL, 
fetal calf ligament; Gla, ,y-carboxyglutamic acid; PYS, parietal yolk sac; 
SMC, smooth muscle cell. 
with several separate strains of BAE and FCL cells derived from primary 
culture. 
Metabolic labeling of cells in vitro with [3H]proline and [35S]methio- 
nine (Amersham Corp., Arlington Heights, IL) was according to Sage et 
al.  0986).  [32p]Orthophosphoric acid  (New  England  Nuclear,  Boston, 
MA) was used as described by Engel et al. (1987).  For determination of 
"y-carboxyglutamic  acid (Gla), [ 14C]glutamic acid (Amersham Corp.) was 
added (5 #Ci/ml) to subconfluent FCL cells in serum-free DME for 24 h. 
Purification of SPARC Protein 
Approximately 20  150-cm 2 plastic tissue culture plates (Falcon Labware, 
Oxnard, CA) of subconfluent PYS (mouse) or FCL (bovine) cells were in- 
cubated in serum-free DME for 18-24 h. The medium was subsequently 
decanted, clarified of cellular debris, and stirred overnight at 4°C in the 
presence of 50%  (wt/vol) ammonium sulfate.  Precipitated proteins were 
concentrated by centrifugation, dissolved in and dialyzed against a  4  M 
urea/50 mM Tris-HCl buffer (pH 8), and chromatographed on DEAE-cel- 
lulose at 4°C. Most of the BSA was eluted with 75 mM NaCl in the same 
buffer,  while SPARC and laminin (PYS cells) or SPARC, fibronectin, and 
type I procollagen (FCL cells) were eluted with 175 mM NaC1 (Sage et al., 
1984,  1986).  We have found that dialysis of this latter fraction against dis- 
tilled water caused SPARC to precipitate selectively. This precipitation oc- 
curred in a relatively narrow pH range (3.5-5.5) and was inhibited by  l0 
mM EDTA.  SPARC was purified further by chromatography on Sephadex 
G-200  in  TBS  at  4°C.  Alternatively,  SPARC  was purified by  carboxy- 
methyl-cellulose chromatography at room temperature in a 2 M urea, 40 
mM Na acetate buffer (pH 4.5),  following an initial denaturation step at 
40°C for 5-10 min. To monitor the purification, one dish of cells was radio- 
labeled  with  [35S]methionine,  but  nonradioactive SPARC  was  used  for 
Western or metal blotting (see below). 
Bovine and mouse SPARC exhibited identical chromatographic and solu- 
bility properties and produced the same results when added to cells. SPARC 
from these two species was used interchangeably for the experiments de- 
scribed in this study. 
SDS-PAGE, protein staining, fluorescence autoradiography, and scan- 
ning densitometry were performed as previously described (Sage et al., 
1986). Molecular weight standards were purchased from Bethesda Research 
Laboratories Inc. (Gaithersburg, MD) and Pharmacia Fine Chemicals (Pis- 
caraway, NJ). 
Studies in Vitro with Exogenous SPARC 
Immunohistological  Studies.  Immunofluorescence microscopy was per- 
formed on cells grown on glass coverslips in vitro as previously described 
(Sage et al., 1984,  1986).  Antibody concentrations were determined by ab- 
sorbance at 280 nm and extrapolation to a standard curve for normal rabbit 
IgG. 
Addition of SPARC to Cells.  Purified SPARC was solubilized in PBS 
at a concentration of 250 ttg/ml as determined by optical density. Increasing 
amounts, from 0 to 10/~l, of SPARC solution were added to 30 #l of DME 
supplemented with 5%  FCS in a 96-well plate. The total  volume of each 
well was then brought up to 40 #1 with PBS, and the plate was equilibrated 
for 10 rain in a 5% C(h incubator at 37°C.  Freshly trypsinized BAE cells 
(fourth passage) were washed by centrifugation in DME/10% FCS, counted 
with a bemocytometer, and diluted to 2  ×  106 cells/ml in DME/5% FCS. 
20 t~l of ceil suspension was added to each well and the plate was returned 
to the incubator for 18 h before photography. Cultures were photographed 
using an inverted phase-contrast microscope (Carl Zciss, Inc., Thornwood, 
NY), and the percentage of rounded vs. spread cells was quantitated by anal- 
ysis of two photographed fields (3  x  5  in) per well. In this manner, a 
dose-response curve was obtained for BAE cells exposed to SPARC. 
For experiments with peptides containing the sequences RGD and RGE 
(control),  10 ttl of a  1 mg/ml stock solution of HPLC-purified GRGDSP 
or GRGESP (gifts from Dr. R. Heimark, University of Washington) in PBS 
were added to wells, and cells were plated as described above with and with- 
out 7 #l/well SPARC solution. 
The biosynthetic products of SPARC-treated and control cells were deter- 
mined as follows: young (fourth passage) primary cultures of FCL cells 
were trypsinized, washed in DME/10% FCS, and resuspended at a concen- 
tration of 1 x  106 cells/ml in DME/I% FCS. 50 #1 of cell suspension was 
added to wells containing 200 #1 of DME/I% FCS and 25 #Ci/mi (L-2, -3, 
-4, and -5)[3H]proline (Amersham Corp.), in the presence or absence of 
6 #1 (3 #g) SPARC solution. 
Conditioned medium was collected after l, 4, 20, and 48 h. Cells were 
washed with 200 #l of PBS, and the pooled medium and wash were clarified 
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concentration by volume) in the presence of0A mg/ml pepstatin A (Penin- 
sula Laboratories, Burlingame, CA). Pellets were washed with 5% trichlo- 
roacetic acid followed by two washes in cold absolute ether and stored over- 
night at -20°C, before solubilization in Laemmli buffer (Laemmli, 1970) 
and analysis by PAGE. The relative amounts of radiolabeled SPARC and 
other proteins were then determined from an autoradiograph by scanning 
densitometry. 
Other experiments were conducted in  12-  and  24-well Costar (Cam- 
bridge, MA) dishes, as well as in 30-mm and 60-mm plates. Stock solutions 
of SPARC,  ranging  from  50  to  500  #g/ml,  were added to appropriate 
volumes of media to produce final concentrations of 0.1-5 #g/ml. Samples 
were dissolved in PBS or DME and were dialyzed against the same buffer 
under sterile conditions. TBS as a  solvent was found to have deleterious 
effects on BAE cells. Control additions included BSA, type I procollagen, 
and laminin; these proteins originated from the same chromatographic run 
(DEAE-cellulose or G-200) as the SPARC sample. Other controls on sepa- 
rate dishes of cells were addition of the sample buffer alone, heat or chro- 
matographically denatured SPARC,  SPARC in combination with afffinity- 
purified anti-SPARC IgG or with normal rabbit IgG, and antibodies alone. 
A minimum of 15 separate preparations of SPARC were used, from both 
bovine and murine cells. 
Preparation  and  Characterization  of  Antibodies.  Native  SPARC 
purified on G-200 was used to generate polyclonal antibodies in adult rabbits 
(Sage et al.,  1989a,b).  IgG, precipitated from whole antisera by addition 
of ammonium sulfate to a final concentration of 20% (wt/vol), was further 
purified by affinity chromatography on Sepharose CL-4B (Pharmacia Fine 
Chemicals) to which had been coupled purified SPARC,  according to the 
manufacturer's instructions. Affinity-purified  anti-SPARC IgG (typical con- 
centrations ranged from 0.1-0.225 mg/ml) were reactive by" ELISA at dilu- 
tions in excess of 1/2,048 and exhibited no reactivity toward BSA or FCS. 
Antibodies were characterized by ELISA, Western blotting, and radioim- 
mune precipitation as previously described (Sage et al.,  1984,  1986). 
Time-lapse Video Microscopy. BAE or FCL cells which had been freshly 
dissociated with trypsin were plated at 2  X  106 cells/ml into T-25 flasks 
containing DME/10% FCS. Control medium was supplemented with PBS, 
while test medium was supplemented with SPARC. Some of the flasks were 
coated with Vitrogen (Collagen Corp., Palo Alto, CA), before plating of 
FCL cells. Immediately after plating, the cultures were briefly incubated at 
37°C  in a  water-saturated 5%  CO2  atmosphere. The caps on the flasks 
were then tightened and the cells were videotaped continuously from 2 h 
to several days. The cells were magnified through a 20× objective attached 
to a Nikon Diaphot inverted microscope equipped with an extra-long work- 
ing phase condenser (Nikon, Inc., Garden City, NY). The cells were im- 
aged through a  video camera (series 65;  Dage-MTl, Inc., Wabash, MI) 
equipped with a high resolution vidicon tube, and were videotaped with a 
time-lapse video recorder (model TLC2051R;  Gyyr Products, Anaheim, 
CA). During the videotaping, the cells were maintfiined within an incubator 
(Nikon, Inc.) attached directly to the microscope, and the temperature was 
regulated at 37°C by an automatic temperature control unit (Nikon, Inc.). 
The videotape was subsequently viewed on a monochrome monitor (model 
925; Lenco, Jackson, MI), and selected frames were photographed directly 
from the screen using a 35-mm camera (Nikkormat) equipped with a 50- 
mm lens. 
Structural Studies 
Circular Dichroism.  Far ultraviolet circular dichroism spectra were ob- 
tained  at  20°C  from  a  Car),  61  spectrometer,  calibrated  with  D(--)- 
pantolactone, with a quartz cell of O.l-mm path length. Protein concentra- 
tions ranged from 0.15  to 0.45  mg/ml  (5.1-15.0  /tM)  in TBS  containing 
2.5-5.0 mM CaCI2 or 12 mM EDTA.  The molar ellipticity, 0,  at 220 nm 
(degree cm2/dmol) was calculated from a mean residue molecular weight 
of 110, determined from the amino acid composition of mouse (PYS cell) 
SPAR(: (Mason et al.,  1986b).  Protein concentration was determined by 
amino acid analysis (performed by Dr. D. Eyre, University of Washington) 
or in some cases from an extinction coefficient, ,-,iw°~28°cm  =  1.076 calcu- 
lated  from  the compositional data  and  the  molecular weight of 33,062 
predicted from the cDNA sequence (Mason et al.,  1986b). 
Gla Analysis.  [J4C]Glutamic  acid-labeled SPARC isolated from FCL 
cells was hydrolyzed in vacuo in I N NaOH at  105°C for 5 h, neutralized 
with 2 M HCt, and lyophilized. Separation of acidic amino acids was per- 
formed essentially as described by McMullen et al. (1983) on a Dowex 5OW- 
X8 column in 13.1 M  ammonium formate, pH 2.2.  Gradient elution was 
achieved with equal volumes (25 ml) of 0.1  ammonium formate, pH 2.9, 
and 0.2 M ammonium formate, pH 3.65. Standards included prothrombin 
(a  girl  from  Dr.  K.  Fujikawa,  University of Washington),  [3H]aspartic 
acid, and [14C]glutamic acid. Detection of radioactive peaks was by liquid 
scintillation counting; nonradioactive amino acids were detected by addition 
of 1.5 ml 0.2 M  NaBO4 (pH 9) to lyophilized fractions, followed by 500 
#1 fluorescamine (Fluoram; Roche Diagnostics, NutIey,  NJ) (300 mg/100 
ml acetone), and fluorimetry at an excitation wavelength of 390 nm and an 
emission wavelength of 480 nm. With this latter method, the limit of sensi- 
tivity was 1 nmol/ml and therefore required a minimum of 0.25/~M (•10 
#g/ml) prothrombin (8 Gla/molecule) and ",,50 #g unlabeled SPARC (as- 
suming  1-2  Gla/molecule).  The occurrence of Gla  in  SPARC was also 
checked by HPLC of base-hydrolyzed protein isolated from FCL cells and 
was performed by Dr. D.  Liska (University of Washington). 
Metal blotting.  Standardized solutions of Ca+2-binding proteins (cal- 
modulin, troponin C) and control proteins including (a) a  Cu+2-binding 
protein (apoazurin; a girl from Dr. E. Adman, University of Washington), 
(b)  an  Fe+2-binding  protein  (transferrin;  Collaborative  Research,  Inc., 
Waltham, MA), and (c) nonmetal-binding proteins (BSA, insulin, and Mr 
standards) were resolved, both reduced and unreduced, on 10 or 15% SDS 
gels and were subsequently transferred electrophoretically to nitrocellulose 
at 0.5 mA for 2 h. Incubation with 45Ca and washing were done following 
closely to the protocol of Davis et al. (1986).  45Ca (0.2, 2, and 20/~M) 
(New England Nuclear) was added to blots previously washed three times 
for  10 min in a 60 mM KCI/5 mM MgCI2/10  mM imidazole buffer (pH 
6.8),  followed by a 5-rain wash in 50% ethanol, air drying, and exposure 
to x-ray  film. To assess the Ca+2-binding  of different domains of SPARC, 
the protein was subjected to  limited cleavage with trypsin (Sage et al., 
1984). 
Enzymatic Assays.  Preparations of SPARC were tested for tissue plas- 
minogen activator activity with a standard assay kit (Spectrolyse) purchased 
from American Diagnostica Inc. (New York). 
Solid-phase  Binding  Assays.  Direct binding assays were conducted in 
polystyrene  96-well  plates  or  in  Removawells  (Immunlon;  Dynatech 
Laboratories, Inc., Alexandria, VA). Native collagen types I (lathyritic rat 
skin), II (bovine cartilage), Ili (bovine skin), IV (human and bovine pla- 
centa),  V  (human fetal  membrane), and VIII (bovine Descemet's mem- 
brane) were prepared in our laboratory by limited pepsin digestion (except 
for type I) and differential salt fractionation (Sage et al., 1981b). Collagens 
were denatured at room temperature in 1 M urea/50 mM Tris-HC1 (pH 7.4); 
in some cases, individual collagen chains or CNBr peptides separated on 
carboxymethyl-cellulose were used. Collagens were solubilized in TBS (50 
t.tg/ml) and adsorbed to polystyrene wells as previously described (Galvin 
et at., 1987). Coating efficiency among the different collagen types, quanti- 
tared by amino acid analysis, was not appreciably different (",~10%) (Parsons 
et al., 1983; Galvin et al., 1987), and adsorption of fibrillar and nonfibrillar 
collagens to plastic surfaces was judged uniform by immunofluorescence 
(Parsons et al., 1983).  Human platelet thrombospondin was a gift from Dr. 
G.  Raugi  (Veterans  Administration Medical Center, Seattle, WA);  human 
plasma fibronectin was a gift from Dr. P. Bornstein (University of Washing- 
ton) or was purchased from Imcera Bioproducts, Inc. (Terre Haute, IN); bo- 
vine endothelial heparan sulfate proteoglycan was a gift from Dr. M. Kin- 
selta (University of Washington); mouse laminin was isolated from PYS 
cells in our laboratory; bovine type VI collagen was a gift from Dr. J. Wu 
(University of Washington); bovine plasma fibrinogen and plasminogen 
were from Dr. E. Davie (University of Washington); and BSA (Pentex, frac- 
tion V) and normal rabbit IgG (Miles Laboratories, Inc., Elkhart, IN) were 
purchased from commercial suppliers.  Human  recombinant tissue plas- 
minogen activator was a gift from Dr. S. Busby (Zymogenetics Inc., Seattle, 
WA). Native SPARC was iodinated with NaJ25I and Iodo-Gen or with Bol- 
ton-Hunter reagent (Pierce Chemical Co., Rockford, IL) and was purified 
either by extensive dialysis against PBS or by passage over Sephadex G-25 
(Pharmacia Fine Chemicals). The iodinated protein migrated as a  single 
Mr 43,000 band on SDS-PAGE and had a specific activity of 1.3-42  ×  l0  t' 
cpm//zg. All proteins used in these assays were examined for purity by SDS- 
PAGE and were quantitated by amino acid analysis, absorbance at 230 or 
280 rim,  or Bradford assay. 
From 0.4 to 12 g.g protein was added to each well in a total volume of 
100 t~l TBS. Quantitation of adsorbed protein was by amino acid analysis 
(AAA Laboratory, Mercer Island, WA) of material solubilized from wells 
in constant boiling HCI. After incubation overnight at 4°C, supernates were 
removed and wells were blocked with  100 ttl ovalbumin (1-10  mg/ml in 
TBS) for 1-2 h at room temperature. After one to two washes in TBS con- 
raining either Ca  +2 or EDTA (see below), 125I-SPARC was added (105-106 
cpm in a total volume of 90-100 al TBS) and incubated at 4"C overnight. 
Conditions were varied with respect to inclusion of Ca  +z or EDTA in TBS 
(Galvin et al., 1987), concentration of coated protein, and amounts of  radio- 
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IgG (39-78 #g of an ammonium sulfate precipitate)  were incubated with 
SPARC  before  addition to  the  blocked  wells.  Wells were  subsequently 
washed two to three times with TBS containing 5-100 mM CaCI2 or 1-10 
mM EDTA, snapped off, and assayed in a  ~/-scintillation counter. 
Results 
Structural Characteristics  of the SPARC Protein 
For functional studies of SPARC, it was necessary to purify 
larger amounts of the protein in an intact, native form than 
had previously been described in the literature. In this re- 
gard, we found that SPARC could be separated from its ma- 
jor contaminant, BSA, by dialysis against water at pH 5.5. 
The acidic pI of SPARC (pI 4.3) is most likely responsible 
for its Ca÷2-dependent  precipitation (Mason et al.,  1986b; 
Engel et al., 1987).  Isolation of SPARC from tissue culture 
medium  in  the  presence  of Ca  +2  and  protease  inhibitors 
resulted in minimal degradation, and subsequent chromatog- 
raphy on Sephadex G-200 in TBS produced a homogeneous 
preparation of SPARC with retention of native structure. In 
Fig.  1 is shown a typical purification on G-200 (Fig.  1 A), 
and the corresponding analysis by SDS-PAGE  of peak area 
II (Fig.  1 B, lanes 1 and 2).  Radioimmune precipitation of 
[35S]methionine-labeled  PYS  cell culture medium proteins 
(Fig. 1 B, lane 3) with afffinity-purified anti-SPARC IgG pro- 
duced a  species of M,  43,000  (Fig.  1 B,  lane 4,  arrow) 
which comigrated with purified SPARC (Fig.  1 B, lane 2). 
Further conformation of the specificity of the antibody is 
shown by the immunoblot of a PYS cell layer lysate (Fig.  1 
B, lane 5). Several preparations of bovine or murine SPARC, 
as shown in Fig.  1 B, lane/), as well as the monospecific 
anti-SPARC IgG, were used for the subsequent experiments 
described in this study. 
The amino acid sequence predicted from mouse SPARC 
cDNA  revealed  two  putative  Ca+2-binding  domains:  the 
glutamic  acid-rich  NH~-terminal  domain  I  and  the  EF- 
hand-containing domain IV (Engel et al.,  1987). We exam- 
ined this binding directly by a blotting procedure in conjunc- 
tion  with  radioactive  metal  ligands.  Cleavage  of  native 
SPARC with trypsin produces two major fragments, one of 
,'oM~ 28,000  (containing domain I) and the other of "-,M~ 
6,000 (containing domain IV) (Sage et al., 1984; Engel et al., 
1987). In Fig. 2 we show that both fragments in the reduced 
form (labeled I and II) bound 4~Ca+2. Control experiments 
showed  that the  EF-hand-containing proteins  calmodulin 
and troponin C also bound the metal, whereas transferrin, 
insulin, and apoazurin were negative (data not shown). Both 
transferrin (~SFe+  9  and apoazurin (64Cu+Z) bound their re- 
spective metal ligands, while BSA and protein markers were 
negative (except  for ~-lactoglobulin  which  bound  45Ca  +2) 
(not shown). The relationship between the micrograms of 
SPARC blotted and the intensity of the band after exposure 
to  the  metal  isotope  was  nearly  linear by  scanning den- 
sitometry. 
It has been estimated that from five to  seven Ca  +2  are 
bound by SPARC domain I (Engel et al.,  1987; Sage et al., 
1989b),  which we speculate has a  lower affinity for Ca  +2 
than that of the EF-hand. The Mr 28,000  fragment retains 
most of the Ca+2-dependent  binding activity towards type 
III collagen that has been shown with the intact protein (Sage, 
H., unpublished experiments; and see experiments below). 
Since the mechanism of Ca  ÷2 binding by domain I  is not 
known, we examined SPARC for the presence of Gla. With 
a lower limit of one residue Gla per molecule of SPARC, we 
were unable to detect this amino acid in SPARC. 
The role of phosphorylation in the function of SPARC is 
unclear.  Although this  posttranslational  modification has 
been reported in bone osteonectin (Uchiyama et al.,  1986) 
and in SPARC from PYS-2 cells (Engel et al., 1987),  it was 
not found in porcine calvarial osteonectin (Domenicucci et 
al., 1988) or in SPARC produced by endothelial cells (Sage 
et al., 1984; and data not shown). Examination of FCL cells 
after an extended labeling showed a minor phosphorylated 
species of Mr 43,000  (data not presented).  We concluded 
that the addition of phosphate group(s) to SPARC is cell or 
tissue-specific and reflects a specialized functional adapta- 
tion.  Furthermore, this posttranslational modification was 
not required for the ability of SPARC to inhibit cell spreading 
in vitro (see below). 
SPARC Inhibits Cell Spreading In Vitro 
In earlier experiments we had shown that SPARC was not 
mitogenic for BAE cells in vitro (Sage et al., 1986). The as- 
sociation of SPARC with proliferating cells also prompted us 
to test its potential activity as a "scatter factor" on Madin- 
Darby canine kidney (MDCK) cells (Stoker et al.,  1987). 
Unlike the fibroblast protein that causes dispersion of epithe- 
lial cells, SPARC in this assay was negative (data not shown). 
We then directed our efforts toward examining the effects of 
exogenous native SPARC on cell behavior in vitro, as well 
as its potential interaction with components of  the extracellu- 
lar matrix. When purified SPARC was added to freshly tryp- 
sinized FCL fibroblasts, the cells failed to spread. This effect 
was seen on collagen-coated as well as plastic substrata in 
the presence of 1-10% FCS. As shown in Fig. 3 A, most of 
the cells plated in medium lacking SPARC were attached and 
spread within 2 h. In contrast, cells plated in the presence 
of SPARC at a concentration of 1.0 #g/ml attached but re- 
tained a rounded morphology (Fig. 3 B). These cells could 
not be dislodged by shaking the dish but could be removed 
by treatment with trypsin/EDTA.  SPARC  in a  native con- 
formation was required for the rounding effect.  After heat 
denaturation, or purification under denaturing conditions, 
SPARC produced the flattened circular dichroism spectrum 
as shown in Fig. 3 Cand was unable to induce rounding. For 
comparison, the spectrum of an active sample is shown in 
Fig. 3 D, with a shoulder at 220 nm signifying the presence 
of o~-helix. Engel et al. (1987) reported an overall  a-helical 
content for a tissue form of SPARC (BM-40) of 25-30 %, and 
a 0220 of -5,600 degrees cmVdmol  -~, which is similar to the 
value we obtained (-4,500  degrees cmVdmol).  The cells 
shown in Fig. 3 B excluded trypan blue (>90%),  incorpo- 
rated [3H]proline into protein, and remained viable for sev- 
eral days. 
Video microscopy was also performed to monitor the re- 
sponse of a given field of FCL and endothelial (BAE) cells 
to SPARC as a function of time. In one experiment, FCL cell 
controls were spread 39 min after plating, while SPARC- 
treated cells were still round at 31 min (data not shown). BAE 
cells, which require somewhat longer times for spreading, 
showed very active membrane activity and began to spread 
at 1 h, 22 min. SPARC-treated BAE cells were rounded after 
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SPARC protein.  [3sS]Methio- 
nine-SPARC was isolated from 
PYS  cell  culture  medium  by 
ammonium sulfate  precipita- 
tion and DEAE-cellulose chro- 
matograpby.  A  fraction  en- 
riched  in  SPARC was  puri- 
fied further  by chromatogra- 
phy  on  Sephadex  G-200  in 
TBS at 4°C.  (A) Elution pro- 
file showing two subfractions 
of  the major peak. Pool II con- 
rained the most homogeneous 
preparations  of SPARC. (B) 
Analysis of SPARC pool II as 
shown in A is depicted in lanes 
1 and 2 of a  10% SDS-POly- 
acrylamide gel. PAGE  was per- 
formed under reducing condi- 
tions, and proteins were stained 
with Coomassie blue (lane 1) 
or were  detected  by fluores- 
cence  autoradiography  (lane 
2). Molecular mass standards 
in  kilodaltons  are  shown  on 
the left. Lanes 3 and 4 show an 
autoradiograph  of [35S]methi- 
onine-radiolabeled  proteins 
secreted  by PYS cells  before 
(lane 3) and after radioimmune precipitation with anti-SPARC IgG and staphylococcal protein A (lane 4). Lane 5 represents a PYS cell 
layer lysate blotted onto nitrocellulose and subsequently probed with anti-SPARC IgG and Protein A. The arrow (on the right) indicates 
SPARC (Mr 43,000) as the specific component  of the radioimmune  complex. 
1 h, 25 min, although a few cells in the process of spreading 
were apparent (not shown). 
The ability of SPARC to inhibit cell spreading was concen- 
tration  dependent.  In  Table I  are  listed  concentrations  of 
SPARC, from 0-42 ttg/ml, with the corresponding percent- 
age of rounded cells scored 24 h after the addition of SPARC. 
The degree of activity varied somewhat with different prepa- 
rations; we now know that this variability is due to the pro- 
portion of native molecules in a given sample. It was a con- 
sistent finding that not all of the cells became round in the 
presence of SPARC.  This result could be due to cellular het- 
erogeneity, position in the cell cycle at the time of addition, 
or internalization of SPARC at 37°C over 24 h. The rounding 
effect was also blunted, although never eliminated, in higher 
concentrations of FCS (10-20%). 
The  biosynthetic profiles of control  and  SPARC-treated 
cells,  examined at several time intervals,  were found to be 
identical.  Moreover, the levels of SPARC production were 
nearly  equivalent  and  were  insignificant  compared to  the 
amounts of exogenous SPARC added to the cultures (data not 
shown). Although it is possible that SPARC was acting as a 
chelating agent in cell culture, we are inclined to believe that 
SPARC was not present in sufficient quantities  in these ex- 
periments to depress  Ca  ÷2 levels below those required  for 
BAE cell spreading.  The concentrations of SPARC used in 
these experiments ranged from 16.7 nM to 1.7 #M, in DME 
containing  1.6  mM  Ca  ÷2.  In related experiments,  we have 
found  that  (a)  cells  spread  normally  in  DME  formulated 
without cations, (b) cell rounding occurred between 0.05 and 
0.1  mM EGTA in  DME without cations in the absence of 
SPARC,  and  (c)  DME  with  cations  containing  0.2  mM 
EGTA  or  0.2  mM  EGTA  plus  SPARC  spread  normally. 
However, cell behavior in the absence of Ca  ÷2 is difficult to 
interpret, and EGTA is known to have deleterious effects on 
the structure of SPARC. 
As shown in Fig.  4,  SPARC had a  marked effect on the 
morphology of BAE cells. Attached, spread cells exposed to 
0.5/zg/ml SPARC in 5 % FCS assumed a rounded morphol- 
ogy but remained attached to the plastic or collagen-coated 
surface (Fig. 4,  compare A with B).  This morphology, as- 
sociated with a lack of spreading, occurred with freshly tryp- 
sinized, attached but subconfluent, and superconfluent cells, 
and  was  seen within  1 h  after addition  of SPARC  (some- 
what longer intervals were required in the case of sprouting 
[Cotta-Pereira  et  al.,  1980]  or  superconfluent  cultures). 
More  SPARC  was  required  to  produce  this  effect  when 
higher  concentrations  of serum  were  used.  The  rounded 
cells, although still attached, could be dislodged by vigorous 
shaking or pipetting; when replated without SPARC, they ap- 
peared as clusters or aggregates (Fig. 4 C) which eventually 
proliferated with the apparent absence of cell spreading (Fig. 
4  D).  The rounded cells synthesized protein and excluded 
trypan blue to the same extent as untreated BAE cells. Type 
I procollagen and BSA, used in equimolar concentrations to 
those of SPARC, had no effect (data not shown). 
Addition  of SPARC  to  sparsely plated  cultures  initially 
caused a  retraction  of the  elongate shape,  followed by the 
rounded morphology seen with confluent BAE cells (Fig. 4 
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amounts (1 #g) of native SPARC protein were incubated at 37°C 
with or without trypsin (0.01 #g), and the digest was resolved by 
SDS-PAGE (10% gel) in the presence (A) and absence (B) of DTT. 
After electrophoretic transfer onto nitrocellulose, the filter was in- 
cubated  with 45Ca+2, washed extensively, and exposed to x-ray 
film. C denotes unincubated enzyme control. The presence of  a sec- 
ond band (M, 40,000) in the lanes (-) that were incubated at 37°C 
without enzyme, is due to an endogenous proteolytic activity in the 
SPARC sample. Trypsin cleavage produced two major fragments: 
I,  the  amino-terminal,  glycosylated  polypeptide  (amino  acids 
1-197) of apparent Mr 28,000; and II, a sequence of ,,oM, 6,000 at 
the carboxyl end of the molecule. Both fragments I and II displayed 
an affinity for Ca  +2. Molecular mass markers in kilodaltons are in- 
dicated on right. 
E). When these round cells (Fig. 4  E) were replated, foci 
of cells  were apparent among  areas  of confluent cells  in 
selected areas of the dishes (Fig. 4 F). Although the round 
cells attached and grew (Fig. 4, D and F), the ability of the 
cells  to  spread  depended  on  the  concentration  of added 
SPARC and on the duration of treatment. Hence, the SPARC- 
treated BAE cells in Fig. 4 D (0.5 ~tg/ml for 24 h) proliferated 
but did not spread even after  10 d  in culture with several 
changes of DME/10 % FCS. In contrast, cells receiving 0.25 
/~g/ml  SPARC  for  6  h  demonstrated  a  cobblestone-like 
monolayer interspersed with foci of round cells within 3 d 
after replating in  fresh DME/10%  FCS in the absence of 
SPARC  (Fig. 4 F). 
A series of control experiments performed with BAE cells 
is  shown  in  Fig.  5.  A  laminin-containing  fraction  from 
Sephadex G-200 (peak I in Fig.  1 A) was ineffective (Fig. 5 
A). BAE cells receiving equivalent amounts of native (Fig. 
5 B) and denatured SPARC (Fig. 5 C) are also shown in Fig. 
5. In the presence of the latter, the cells proliferated and ap- 
peared, 24 h later, as a normal endothelial monolayer (Fig. 
5  C).  That the effect of SPARC  was  specific was demon- 
strated by  incubation of 0.75  /~g/ml  SPARC  with  affinity- 
purified anti-SPARC IgG. As shown in Fig. 5 D, there was 
no observable effect on cell morphology in the presence of 
the  immune complexes.  Antibody alone or normal  rabbit 
IgG  was  also  without  effect on  the  monolayer  (data  not 
shown). 
Although SPARC inhibited spreading in cultures of bovine 
endothelial cells and fibroblasts, not all the cells that we ex- 
amined were affected in a similar manner. The transformed 
murine cell lines PYS-2 and F9 (undifferentiated) did not re- 
spond to SPARC,  and the 3T3 cell line also was  refractory 
(data not shown). Bovine SMC exhibited a lesser response, 
scored  as  percent  of rounded  cells,  than  was  seen  with 
equivalent concentrations of SPARC added to BAE and FCL 
cells. These results, as well as the biochemical controls al- 
ready described, show that the effect of SPARC was not one 
of overall toxicity or inhibition of a general cellular meta- 
bolic pathway.  Primary cells (e.g., murine skin fibroblasts), 
or cells at low passage,  isolated from nonmalignant tissue, 
also were sensitive to added SPARC. 
The effect of SPARC  on BAE cells also appeared to be 
independent of  the rounding phenomenon produced by a syn- 
thetic peptide containing the sequence RGD.  In Fig.  6 are 
shown cultures that received RGD (Fig. 6, A, D, and G) and 
RGD plus SPARC (Fig. 6, B, E, and H), photographed at 1 
(Fig. 6, A-C), 4 (Fig. 6, D-F), and 10 h (Fig. 6, G-I) after 
the addition. While both reagents caused a similar rounded 
morphology, after 10 h the RGD effect was diminished (pos- 
sibly  because  the  cells  synthesized  additional  receptors 
and/or attachment proteins). Cells in the presence of RGD + 
SPARC,  however, remained largely unspread.  The control 
peptide RGE had no effect on the cells (Fig. 6 F), and it did 
not alter the ability of SPARC to inhibit cell spreading (Fig. 
6,  C and I). We have also recently observed that the anti- 
endothelial  cell  vitronectin receptor monoclonal antibody 
LM609 (Cheresh, 1987) did not interfere with the rounding 
of BAE cells plated onto SPARC-coated dishes (Cheresh, D., 
and H. Sage, unpublished experiments). These experiments 
suggest that SPARC affects cells independently from an RGD- 
related mechanism, in that the cells were unable to use alter- 
nate means for spreading in the presence of SPARC. 
Immunofluorescence localization of exogenous SPARC on 
sparsely plated BAE cells is shown in Fig. 7. The protein was 
concentrated at the leading edges of membranous extensions 
(Fig. 7 B), which were barely perceptible by phase micros- 
copy (Fig. 7 A, arrows). SPARC was not bound in detectable 
amounts onto the plastic surface; there was minimal extracel- 
lular matrix produced by these <24-h cultures. This finding 
is consistent with the binding of SPARC to BAE cell surfaces, 
especially in the areas of membranous ruffling. We have also 
recently demonstrated that  ~2sI-SPARC binds to BAE cells 
with high affinity (Sage, H., and S. Funk, unpublished ex- 
periments). 
SPARC Binds to Several Components of the 
ExtraceUular Matrix 
A solid-phase binding assay was used to measure the affinity 
of native radiolabeled SPARC for certain components of the 
The Journal of Cell Biology, Volume  109, 1989  346 Figure 3. Effect of native SPARC on fibroblasts in vitro. (A and B) FCL fibroblasts were trypsinized and plated on collagen-coated plastic 
in DME/10% FCS in the absence (A) or presence (B) of native SPARC (1.0/~g/ml). In A (2 h after plating), the majority of cells are attached 
and spread.  In B, cells in the presence of SPARC for 2 h have attached (during the first 15 min after plating) but have failed to spread. 
(Cand D) Circular dichroism spectra of denatured (C) and native (D) SPARC. SPARC (0.15 mg/ml, 5.1 #M) in TBS containing 2.5 mM 
CaC12 was measured  at 20°C.  The shoulder  at 220 nm (arrow) in D is indicative of t~-helical content;  022o was calculated as  -4,500 
degrees cm2/dmol. This sample elicited the rounded morphology as shown in B. In contrast,  the spectrum in C shows a sample of dena- 
tured SPARC that was ineffective on the cells,  resulting in a morphology  similar to that shown in A. Bar, 30/zm. 
blood clotting cascade,  as well as secreted proteins which 
contribute to the formation of basement membranes or ex- 
tracellular matrices. 25 separate assays, performed with sev- 
eral  preparations of radiolabeled  SPARC  and  a  variety of 
experimental conditions, produced reproducible trends.  In- 
dividual experiments have been shown to illustrate internal 
Table L Relationship between SPARC Concentration and 
Inhibition of BAE Cell Spreading on Plastic Substrata* 
SPARC addition  Rounded cells~: 
izg/ml  % 
0  9.0 
2.0  14.5  +  1.5 
4.0  43.5  -I- 0.5 
12.5  46.0  -I- 0 
20.0  52.5  +  2.5 
29.0  61.0  +  5.0 
42.0  68 
* Trypsinized  BAE  cells  were  resuspended  in  DME/5%  FCS  at  2  x  106 
cells/ml.  Equal aliquots  (20 /zl each)  were added  to microtiter  wells  in the 
presence of increasing concentrations  of native murine SPARC.  Scoring was 
performed  24 h later on two photographed  fields. 
Expressed as mean  +  SEM. 
consistency;  measurements  varied  from  2-12%  (SEM). 
Since SPARC can form a complex with BSA under certain 
conditions (Sage et al.,  1984; Domenicucci et al., 1988), we 
routinely subtracted counts per minute of SPARC bound to 
control (BSA-coated) wells and used ovalbumin as a blocking 
agent. 
The most significant interaction between  '25I-SPARC and 
these proteins was observed with thrombospondin and native 
collagen types III and V (Table II and Fig. 8). Incubation of 
~25I-SPARC with anti-SPARC  IgG, before addition  to pro- 
tein-coated wells, resulted in an 84-94% inhibition of bind- 
ing (data not shown).  Between 0.26 and  1.62 pmol SPARC 
were bound per picomole of collagen types I-V (Table II). 
Conversion of picomoles adsorbed collagens to molar con- 
centrations (0.17-2.8  x  10  -s M) showed that the amounts of 
SPARC bound to collagen were from 20 to 300 times higher 
than  those  reported  by Galvin et al.  (1987)  for thrombo- 
spondin bound to collagen in the presence of Ca  ÷2 (~9 fmol 
thrombospondin bound to type V collagen at a concentration 
of 10  -8 M).  Fig.  8 A shows a  comparison of the affinity of 
SPARC for several of these proteins. Wells coated with type 
III collagen clearly demonstrated the highest level of bind- 
ing, which was linear with respect to the amounts of collagen 
adsorbed to the wells (not shown).  Native type V  collagen 
exhibited greater affinity for SPARC than types I, II, and IV 
Sage et al. SPARC Binds to Matrix and Inhibits  Cell Spreading  347 Figure 4.  SPARC affects endothelial cell morphology and growth. 0.5 ~tg/ml SPARC in PBS was added to confluent BAE cells in DME 
containing 5% FCS. (A) Control receiving PBS alone; (B) 24 h after SPARC addition. Round cells in the presence of SPARC were detached 
with a stream of medium and were replated in fresh DME containing  10% FCS in the absence of SPARC. (C) 24 h after replating; (D) 
culture shown in C after 1 wk. A subconfluent BAE culture in 2.5%  FCS received 0.25/zg/ml  of highly purified native SPARC. (E) 6 h 
after addition '~10% of the cells were detached; (F) 3 d after replating of detached cells in E, ,~50% of the cells were attached. Differences 
observed between the cells in D and F are largely due to the amount of SPARC initially added to the cells, as well as the duration of treatment 
with SPARC before replating after its removal. Bar, 50 #m. 
(Table II and Fig.  8).  When a  complex between thrombo- 
spondin and type V collagen was formed in the presence of 
EDTA (Galvin et al.,  1987),  and tested  in  the  assay with 
~2q-SPARC, binding was generally greater for the complex 
than for each component alone (not shown).  However, the 
results were variable and were found to be extremely sensi- 
tive to the concentration of Ca  ÷2 in the binding buffer (data 
not shown). We found minimal binding of SPARC to lami- 
nin;  in  addition,  background  levels  (similar  to  those  ob- 
tained with BSA-coated and blocked wells)  were observed 
with fibronectin, tissue plasminogen activator, GRGDSP and 
GRGESP (Fig.  8 A), fibrinogen (Table II), type I procolla- 
gen, types VI and VIII collagen, heparan sulfate proteogly- 
can,  and  plasminogen (data not  shown).  Binding  to dena- 
tured  collagens,  including  gelatin  as  previously  reported 
(Sage et al.,  1984),  was also low. 
Fig. 8 B illustrates the effect of Ca  ÷2 concentration on the 
binding of SPARC to types I, III, and V  collagen.  An  in- 
creased association of t25I-SPARC with these collagens was 
seen between Ca  +2 concentrations  of 18  and  37  raM.  The 
dissociation constant (Kd) for the affinity of SPARC for type 
III collagen was calculated from Scatchard analyses of the 
data shown in Fig.  8 B  to be •0.5  nM. 
The ability of SPARC to elicit endothelial  cell rounding 
could be mediated by its association with type III collagen. 
To examine this  possibility,  we performed the  experiment 
shown in  Fig.  9.  BAE cells plated on type III collagen at- 
tached and spread readily within 24 h (Fig. 9 A), and prolif- 
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inhibited by denaturation and by anti-SPARC IgG. 
Cultures of subconfluent BAE cells in DME con- 
mining 5% FCS were incubated with 0.5--0.75/~g/ml 
murine SPARC that was purified on Sephadex  G-200 
under native conditions (B).  A fraction containing 
laminin from the same chromatographic procedure 
was added to replicate cultures (•50-fold  Molar ex- 
cess over the concentration of SPARC) (A). Heat 
denaturation of the SPARC sample used in B (5 min 
at 70°C) produced an inactive protein as shown in 
C. In D, confluent BAE cells received 20 td rabbit 
anti-mouse  SPARC |gG ("~35-fold Molar excess), 
in the presence of 0.75 /~g SPARC that had been 
preincubated with the antibody. Cultures were pho- 
tographed 24 h later. Bar, 50/~m. 
erated to near confluence after 4 d (Fig. 9, B-D). In contrast, 
cells plated on substrates of type III collagen which had been 
preincubated with SPARC were round after 24 h (Fig. 9 E) 
and failed to spread at the end of 4 d (Fig. 9, F-H).  In the 
presence of SPARC,  however, proliferation was not dimin- 
ished (Fig. 9, compare D  and H). This result suggests that 
the antispreading activity of SPARC could be amplified by 
its association with an extracellular matrix protein.  More- 
over, SPARC was fully functional when complexed with type 
III collagen. 
Discussion 
From the preceding experiments, we have made several ob- 
servations  concerning  the  properties  and  function(s)  of 
SPARC:  (a) the protein induced a  rounded morphology in 
confluent monolayers of bovine SMC,  fibroblasts,  and en- 
dothelial cells; (b) SPARC maintained the rounded morphol- 
ogy of newly plated (trypsinized) cells and inhibited their 
spreading;  (c) rounded cells retained viability, synthesized 
protein, and exhibited a capacity for proliferation subsequent 
to  replating  in  the  absence  of SPARC;  (d)  the  effect of 
SPARC was specific, concentration dependent, and required 
native structure; (e) SPARC did not inhibit cellular aggrega- 
tion; (f) BAE cells, rounded in the presence of GRGDSP, be- 
gan to spread after 10 h, while cells treated with SPARC did 
not; (g) SPARC was associated with BAE cell plasma mem- 
branes;  and (h) SPARC  bound specifically, and  in a  Ca  +2- 
dependent manner, to types III and V collagen. 
These results, and experimental data from prior studies in 
vascular biology, support the following hypothesis for the ac- 
tivity of SPARC  in the endothelial extracellular space. We 
have shown (Sage et al., 1986) that injury to endothelial cells 
results  in an  increase in the secretion of SPARC.  Throm- 
bospondin and type V collagen, two major proteins of the ex- 
tracellular matrix and subendothelium (Sage et al.,  1981a; 
Wight et al.,  1985), form a complex in low concentrations 
of Ca  ÷2 (Mumby et al.,  1984b;  Galvin et al.,  1987);  dissoci- 
ation occurs when the Ca  ÷2 concentration is >30 #M (Gal- 
vin et al.,  1987). Based on their relative affinities for each 
Sage et al. SPARC Binds to Matrix and Inhibits Cell Spreading  349 Figure 6.  SPARC and a peptide GRGDSP inhibit endothelial cell spreading by independent mechanisms.  Freshly trypsinized BAE cells 
were plated on plastic in DME containing 5% FCS.  10 #g GRGDSP, 10 #g GRGESP, and/or 0.5 #g SPARC were added in a total volume 
of 200 #l for the indicated times.  Cultures shown in A, D, and  G  received RGD; those in B, E, and H  received RGD and SPARe; and 
C and 1 received RGE and SPARC. The cells in F  were cultured in RGE alone.  While both SPARC and RGD caused a similar rounded 
morphology, after  10 h the effect of RGD was diminished (G).  In contrast,  cells in the presence of RGD plus SPARC remained largely 
unspread  after  10 h  (H).  Bar, 50/zm. 
The Journal of Cell Biology, Volume 109, 1989  350 Figure 7.  Immunofluorescence localization of SPARC on the en- 
dothelial cell surface. To freshly trypsinized cells was added 0.5/~g 
SPARC; 21 h later, the cells were fixed after several washes and ex- 
posed sequentially to rabbit anti-mouse  SPARC IgG and FITC- 
goat anti-rabbit  IgG. (A) Phase-contrast image of the same field 
shown as immunofluorescence image in B. Arrows indicate areas 
of cell membrane that are barely visible in A but that label strongly 
with the anti-SPARC antibody in B. Bar, 30/~m. 
other and possibly for Ca  ÷2,  SPARC  and type V  collagen 
might interact with a  transfer of Ca  ÷2, leading to dissocia- 
tion of type V collagen and thrombospondin. Alternatively, 
SPARC could bind to thrombospondin to dissociate the puta- 
tive complex. Type V  collagen could then be cleaved spe- 
cifically by thrombin (Sage et al.,  1981b), followed by a dis- 
solution of the matrix that would facilitate endothelial cell 
proliferation. Native thrombospondin, which binds up to 12 
Ca  ÷2 (with an overall low affinity of ,'~10  -4 M) (Lawler and 
Hynes,  1986), has been shown to promote cell attachment 
and proliferation, and to function as a platelet lectin (Frazier, 
1987).  On  the other hand,  the selectively high affinity of 
SPARC  for type III  collagen,  a  major  component of the 
subendothelium and  tuniea  media  of large  vessels  (Sage, 
1986a, and references therein), is suggestive of  another mech- 
anism involving this collagen and/or other ligands. 
After the experiments described in this report were com- 
pleted,  Clezardin et al.  (1988) published  similar observa- 
tions regarding complex formation between thrombospondin 
and osteonectin purified from bovine bone and human plate- 
lets.  EDTA-treated osteonectin was  inactive,  and  a  Kd  of 
0.86 nM was reported for binding of soluble thrombospondin 
to  solid-phase-adsorbed osteonectin. Although in these re- 
spects our results are similar,  Clezardin et al.  (1988)  were 
unable to demonstrate competitive binding between throm- 
bospondin and type I collagen, type IV collagen, or BSA for 
solid-phase-adsorbed osteonectin. We have shown immuno- 
logic  as  well  as  structural  differences  between  SPARC 
purified from platelets and cell culture (Mann, K., and H. 
Sage, unpublished experiments). Alternatively, SPARC  ad- 
sorbed to microtiter wells is likely to exhibit different proper- 
ties from that in solution, especially with respect to availabil- 
ity of binding sites that are in turn dependent on a  native 
conformation. Although we have demonstrated binding of 
SPARC to thrombospondin, on a molar basis this level was 
low when compared to the affinity of SPARC for collagen, 
especially types III and V. 
Since earlier studies had claimed that osteonectin selec- 
tively bound to the organic phase of bone (Termine et al., 
1981) and to partially purified preparations of type I collagen 
(Romberg et al., 1985), we suggest that the binding observed 
by these investigators was due to these other collagens which 
have been shown to copurify with type I. Gelatin has been 
shown  not  to be a  ligand  for SPARC  (Sage et al.,  1984; 
Domenicucci et al.,  1988), while EDTA-extracted SPARC 
also did not bind to native type I collagen (Domenicucci et 
al.,  1988).  This result  is  consistent with the Ca+2-depe  n- 
dent binding properties of SPARC  that we describe in this 
study. 
We presently do not understand the extent or mechanism 
of Ca  ÷2 binding by SPARC.  Sequencing of the bovine and 
Table II.  Binding of 1251-SPARC to Immobilized 
Extracellular Proteins* 
Protein  SPARC bound/protein 
pmol/pmol 
Collagen type I  0.26 
Collagen type II  0.62 
Collagen type III  1.62 
Collagen type IV  0.59 
Collagen type V  0.96 
BSA  0.022 
Fibrinogen  0.11 
* Proteins were coated at 5  /~g/well;  picomoles of protein adsorbed to each 
well  were calculated by amino acid analysis. 7  x  104 cpm '25I-SPARC were 
added per well  (2.2  x  107 cpm/~tg).  Replicate  determinations (2--4)  (Sage 
et al.,  1986;  Nicosia and Madri,  1987;  Rodgers,  1988)  produced values + 
2-12%  SEM. 
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Figure 8. Binding of 125I-SPARC tO components of the vascular ex- 
traceUular matrix. (,4) Affinity of t25I-SPARC for different ligands. 
Types I, III, and V collagen, BSA, fibronectin (FN), thrombospon- 
din (TSP), tissue plasminogen activator OPAL and the peptides 
GRGDSP (RGD) and GRGESP (RGE) were coated onto polysty- 
rene wells at concentrations of 25-50 ttg/ml. After additional reac- 
tive sites on the plastic were blocked with ovalbumin (1 mg/ml), 
wells received from 25,000 to 100,000 cpm m:sI-SPARC and were 
incubated 10-16 h at 4°C. Subsequent to several washes, each well 
was detached and counted in a gamma counter. Data shown are 
from two experiments but are representative of  25 experiments. Er- 
ror bars show mean 5: SEM (n =  2). (B) Ca+2-dependent binding 
of ~25I-SPARC to collagens. Types I,  III,  and  V collagen were 
coated as described in A. After the blocking step, wells were washed 
twice with TBS containing 1 mM EDTA, or TBS containing from 
1 tO 75 mM CaC12.  ~25I-SPARC  was subsequently added in the ap- 
propriate buffer and allowed  to bind from 10 to 16 h at 4°C. Washing 
was performed with the same binding buffer, and wells were mea- 
sured individually for radioactivity in a gamma counter. Data (rep- 
resentative of five experiments) are shown from a single experiment 
(in triplicate) and are plotted as mean  5: SEM (n  =  3). 
mouse genes revealed an unusual degree of hypervariability 
in exon 3, which codes for domain I, the glutamic acid-rich 
region purportedly responsible for most of the Ca  ÷2 bound 
by this protein (Findlay et al., 1988; McVey et al., 1988). At 
the present time the significance of this lack of conservation 
is not known. Despite the prevalence of  glutamic acid repeats 
in domain I, we were unable to demonstrate either the pres- 
ence of Gla or convincing similarities between SPARC and 
several  vitamin  K-dependent  coagulation  zymogens  and 
plasma proteins (Friedman and Przysiecki,  1987),  matrix 
Gla protein (Price et al.,  1987), or the consensus sequence 
for  the  B-hydroxyAsp or  /3-hydroxyAsn  modification  de- 
scribed  in  several  coagulation and  anticoagulant  proteins 
(Ohlin et al., 1988). In contrast, SPARC domain IV contains 
a consensus E-F-hand sequence (Engel et al.,  1987) which 
is  similar  to  certain  of the  Ca+2-binding  regions  of the 
fibronectin  receptor  (Hynes,  1987)  and  thrombospondin 
(regions 1 and 2) (Frazier, 1987). These regions are referred 
to as "EF-elbows" and may confer a structural advantage to 
extracellular proteins which bind Ca  ÷2 or other metals. 
The putative extracellular interaction of SPARC with pro- 
teins of the subendothelium could occur without invocation 
of Ca  +2, since it is possible that the cation subserves an ex- 
clusively structural role in the conformation of the SPARC 
protein. A potential problem with our hypothetical model is 
the micromolar concentration of Ca  ÷2 in the cytosol vs.  its 
mM concentration outside the cell. If, as current beliefs per- 
tain,  cells  are  uniformly exposed to  millimolar levels of 
Ca  +2, how can high-affinity binding sites (e.g., an EF-hand 
with Kd of 10-6-10  -7 M) release or modulate their Ca+E? Al- 
though there are few data that directly address this point, we 
offer the  following explanations  for the  feasibility of our 
model: (a) The activity of millimolar Ca÷2-dependent  pro- 
tease found in sarcoplasmic reticulum (0.1-0.2/zM Ca  ÷2 in 
the resting state) is thought to depend on specific inhibitor 
levels (Otsuka and Goll,  1987); (b) microdomains of high 
density surface charges, created by membrane glycoproteins, 
are known to render cell surfaces nonuniform; (c) the Ca  ÷2- 
sensitive c~-subunit of the vitronectin cell surface receptor 
projects six EF-hands into the extracellular space, although 
their role is presently unclear (Hynes, 1987); (d) maximal 
aggregation of the basement membrane proteins laminin and 
nidogen (entactin) occurred at 50 mM Ca  +2, although the 
complex showed 16 binding sites for Ca  ÷2 with Kd'S from 5 
to 300 mM (Paulsson,  1988); (e) SPARC may bind another 
cation competitively (e.g., as Mg  +2 is bound by prothrom- 
bin (Deerfield et al., 1987); and (/') in a ternary complex the 
Kd for Ca  +2 may be affected by phospholipid or another pro- 
tein (Deerfield et al., 1987; Lambers et al., 1987). A ternary 
complex involving thrombospondin, plasminogen, and histi- 
dine-rich glycoprotein has in fact been reported (Silverstein 
et al.,  1985). 
The formation of protein complexes may have relevance to 
endothelial cell behavior, particularly with respect to the as- 
sociation of enzymes with their inhibitors. Silverstein et al. 
(1986) have reported that the association of thrombospondin 
with plasminogen was enhanced by plasminogen activators. 
Urokinase-type plasminogen activator, a component of local 
adhesion plaques and migrating endothelium, has been im- 
plicated  in  cellular migration  by "directional proteolysis" 
(Pepper et al.,  1987;  P611~inen et al.,  1988).  The recent 
finding of Ca-dependent protease II, together with one of its 
substrates (talin) in adhesion plaques, supports the concept 
of an extracellular regulatory role for protease-protease in- 
hibitor complexes (Beckerle et al., 1987). Both plasminogen 
activator-inhibitor and another soluble inhibitor of serine 
proteases, protease nexin-1, are associated with the extracel- 
lular matrix and are thought to control in part its proteolysis 
(Farrell et al.,  1988; Knudsen and Nachman,  1988). Exten- 
sive homology searches have failed,  however,  to  identify 
SPARC with any of these proteins, and activities resembling 
The Journal of Cell Biology,  Volume  109, 1989  352 l~gure 9. SPARC bound to type III collagen inhibits spreading of BAE cells. Plastic petri dishes were coated with native type III collagen 
in PBS (200 ttg/well) overnight at 4°C, washed five times with PBS, and some dishes were incubated with SPARC (30-50 ttg/well) overnight 
at 4°C.  After several additional washes with PBS, trypsinized BAE cells resuspended in DME containing 5% FCS were plated at equal 
densities onto substrates of type III collagen alone (A-D) or SPARC bound to type III collagen (E-H). Photomicrographs were taken 24 
(A and E), 48 (B and F), 72  (C and G), and 96 h (D and H) after plating. Bar, 50/~m. 
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gen activator-inhibitor were absent from purified prepara- 
tions of SPARC (S. Carson, University of Colorado, Denver, 
CO;  and D.  Loskutoff, The Research Institute of Scripps 
Clinic, La Jolla, CA; unpublished experiments). A limited 
region within SPARC  domain II, on the other hand, was 
found to be related to sequences of the protease inhibitors 
ovomucoid (third domain), pancreatic secretory trysin-type 
protease inhibitor, and acrosin inhibitor I (Engel et al., 1987; 
Bolander et al., 1988). Although this similarity may indicate 
a role for SPARC as an inhibitor of extracellular proteolytic 
activity, the sequence conferring inhibitory activity to ovo- 
mucoid is not represented in SPARC. 
The ability of extracellular matrix proteins to modulate 
cellular phenotypes and growth has now been amply demon- 
strated for several matrix constituents (Herman and Castel- 
lot,  1987; Ben-Ze'ev et  al.,  1988;  Farrell  et  al.,  1988). 
Fibronectin has been shown to stimulate the differentiation 
of neural  crest  cells  into  adrenergic  cells,  to  inhibit the 
differentiation of myoblasts into myotubes, and to promote 
dedifferentiation  of  chondrocytes  to  mesenchymal  cells 
(Ruoslahti, 1988). Laminin stimulates neurite outgrowth and 
neuronal differentiation (Martin and Timpl, 1987). Process- 
es which regulate endothelial cell angiogenesis in vitro are 
modulated by components of  the basement membrane as well 
as by a  laminin-binding protein (Form et al.,  1986;  Yan- 
nariello-Brown et al.,  1988).  It is likely that these effects 
are mediated by cell surface receptors which, in the case of 
RGD receptors or integrins, function as transmembrane pro- 
teins that interact with cytoskeletal elements via talin and 
vinculin (Buck and Horwitz, 1987; Hynes, 1987). Distribu- 
tion of these receptors in vitro is partially dependent on the 
type and accumulation of extracellular matrix (Singer et al., 
1988).  Occupancy of cell surface receptors may also result 
in metabolic changes, such as protein phosphorylation, which 
could, in turn, modulate gene expression (Yarden and Ull- 
rich,  1988). 
Our experiments suggest that the rounding effect elicited 
by SPARC on BAE cells occurred by a mechanism which did 
not disrupt intercellular adhesion nor RGD receptor-medi- 
ated cell-substratum adhesion (Ginsberg et al., 1988). BAE 
cells are responsive to certain of the components of extracel- 
lular matrix. Cheresh (1987) has shown that human endothe- 
lial cells synthesize an RGD-directed adhesion receptor that 
mediated cellular attachment to vitronectin, fibrinogen, and 
von Willebrand factor.  Although the platelet glycoprotein 
complex GP IIb/IIIa, another member of the integrin family 
of receptors using the peptide sequence RGD, was shown to 
facilitate adhesion of human endothelial cells to the BAE ex- 
tracellular matrix or to purified matrix proteins (Charo et 
al., 1987; Chen et al., 1987), antibodies to this complex did 
not affect initial cellular attachment (Chen et al.,  1987). 
Tenascin (also called cytotactin) (Jones et al.,  1988),  a 
secreted  protein  unrelated  to  SPARC,  also  produced  a 
rounded morphology when added to fibroblasts and inhibited 
the attachment of these cells to RGD-containing proteins 
such as  fibronectin (Chiquet-Ehrismann et al.,  1988).  In 
contrast, Herbst et al. (1988) have shown that type IV colla- 
gen  selectively promoted RGDS-independent adhesion of 
BAE cells. Since SPARC bound selectively to components of 
the extracellular matrix which might be used by BAE cells 
as attachment and/or spreading factors, it is possible that 
SPARC would disrupt the association and cause the cells to 
become rounded. It appears that endothelial cells can attach 
to substrata by mechanisms other than RGD-directed recep- 
tor(s). We propose that SPARC interferes with one or more 
of these alternate mechanisms. 
We also propose that SPARC and thrombospondin share 
potentially similar roles in the regulation of endothelial cell 
behavior. Both proteins are secreted at increased levels by 
sparsely plated, growing cells (Mumby et al.,  1984a;  Sage 
et al.,  1986).  Thrombospondin undergoes receptor-medi- 
ated binding and degradation by endothelial cells (Murphy- 
Ullrich and Mosher, 1987) and has been implicated as an es- 
sential component in the growth of SMCs (Majack et al., 
1988). Part of this mechanism may involve binding of throm- 
bospondin to sulfated glycolipids of the plasma membrane 
(Roberts et al.,  1985),  to a cell surface receptor (Murphy- 
Ullrich and Mosher, 1987),  to bona fide constituents of the 
extracellular matrix such as type V collagen and heparan sul- 
fate proteoglycan (Mumby et al., 1984b;  Frazier, 1987), or 
to SPARC (Clezardin et al., 1988 and this work). The con- 
formational changes resulting from such interactions could 
contribute to dissolution of cell-matrix contacts as an auto- 
crine  or  paracrine  response  to  signals  directing  cellular 
migration or proliferation. 
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